Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alpelisib long-term safety rollover study after prior Novartis-sponsored alpelisib trials
CTR20263478Phase 2Active
- Sponsor
- Novartis
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alpelisib in breast cancer, PIK3CA-related overgrowth spectrum (PROS), sponsored by Novartis. Started Sep 2026; status: active.
02
Drugs
alpelisib
03
Conditions
breast cancerPIK3CA-related overgrowth spectrum (PROS)
Beyond the preview
Go deeper on CTR20263478.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263478.